Sabby Management, LLC Cingulate Inc. Transaction History

Sabby Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.69 - $328.8 $66,084 - $31.5 Million	-95,775 Reduced 81.31%	22,018 $22,000
Q3 2022 Nov 14, 2022	SELL	$0.26 - $420.0 $105,777 - $171 Million	-406,837 Reduced 77.55%	117,793 $126,000
Q2 2022 Aug 15, 2022	SELL	$259.2 - $453.6 $59.5 Million - $104 Million	-229,500 Reduced 30.43%	524,630 $766,000
Q1 2022 May 16, 2022	SELL	$278.4 - $698.4 $36.8 Million - $92.3 Million	-132,124 Reduced 14.91%	754,130 $1.49 Million
Q4 2021 Feb 14, 2022	BUY	$556.8 - $1068.0 $493 Million - $947 Million	886,254 New	886,254 $2.45 Million

Ticker CING
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,309,400
Market Cap $53.8M
Description
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-de...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.